A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Vardenafil

Phosphodiesterase 5 Inhibitor class · 5 generic manufacturers · 22 ANDAs filed at FDA.

First FDA approval2018-10-26
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$642,093 in CY2024 Part D spend6K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
$2.23/unit
16 NDCs benchmarked, lowest of all strengths.
Average NADAC
$5.99
Across all dosage forms in distribution.
Highest NADAC
$20.90
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Vardenafil used for?

Vardenafil is a Phosphodiesterase 5 Inhibitor medication tracked in Medicare Part D.

Is there a generic for Vardenafil?

Yes. 22 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Vardenafil?

Across 329 Part D plans, Vardenafil averages $5.99/unit (NADAC). Lowest available: $2.23/unit. Highest in distribution: $20.90/unit.

Is Vardenafil on the FDA shortage list?

No. Vardenafil is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Phosphodiesterase 5 Inhibitor3 alternatives in D1
01
Avanafil
Phosphodiesterase 5 Inhibitor
$42.14Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →
02
Sildenafil
Brand: Revatio
$0.053Lowest NADAC
25Generic mfrs
$66.0MCY24 Part D spend
Compare →
03
Tadalafil
Brand: ADCIRCA
$0.104Lowest NADAC
28Generic mfrs
$161.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (16 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.